Can-Fite Biopharma Debt to Equity

The latest debt-to-equity ratio for CANF is 0.09. That is below the Healthcare sector average of 0.31. Investors often review this figure alongside Can-Fite Biopharma's historical trend and sector peers before judging valuation or financial health.

Against Healthcare companies, CANF currently prints 0.09 for debt-to-equity ratio, while the sector average sits near 0.31. That is roughly 72.4% below the sector mean. Large gaps often invite a closer look at Can-Fite Biopharma's growth, margins, and balance sheet.

A debt-to-equity ratio of 0.09 for Can-Fite Biopharma is not 'good' or 'bad' on its own. Compare it with the peer average (0.31) and with CANF's multi-year chart on this page. Persistently elevated multiples need growth or quality to justify them; depressed multiples need a catalyst or evidence the business is misunderstood.

After noting CANF's debt-to-equity ratio (0.09), review year-over-year change, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.

This page's peer comparison chart is the fastest way to stack Can-Fite Biopharma's debt-to-equity ratio against similar Healthcare names. You can also browse sector and industry screens on Stockcircle for a broader set of Healthcare companies and their key multiples and fundamentals.